Welcome to our dedicated page for Alamar Biosciences SEC filings (Ticker: ALMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Alamar Biosciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Alamar Biosciences's regulatory disclosures and financial reporting.
Alamar Biosciences, Inc. reported that board member Ian Ratcliffe, an independent director since February 2024, passed away on July 5, 2026. The company expressed condolences and acknowledged his dedication and service.
Following his passing, the board reduced the authorized number of directors constituting the full board to five and appointed Nicholas Naclerio, Ph.D., to the Audit Committee of the board.
Alamar Biosciences, Inc. shareholder Sands Capital Life Sciences Pulse Fund II, L.P. reports beneficial ownership of 4,230,926 shares of common stock, or about 6.1% of the company. This percentage is based on 69,311,186 shares outstanding as of April 30, 2026.
The shares are held for investment purposes, and the reporting group may buy or sell more stock over time. Following the passing of Ian Ratcliffe on July 5, 2026, the group no longer has a representative on Alamar’s board and states it does not currently intend to seek board representation, while reserving flexibility on future plans.
Alamar Biosciences disclosure: Sherpa-related entities and manager Daqing Cai reported beneficial ownership of 4,972,134 shares of Common Stock, equal to 7.2% of the class. The filing breaks ownership into 3,970,446 shares by Sherpa Healthcare Fund II, L.P. and 1,001,688 shares by Sherpa Healthcare Co-Investment Fund, L.P. The percentage figures use a base of 69,311,186 shares outstanding as of April 30, 2026, per the company Form 10-Q.
Alamar Biosciences, Inc. reported strong top-line growth for the quarter ended March 31, 2026, with revenue rising to $26.0 million from $13.1 million a year earlier, driven by higher instrument placements and rapidly expanding consumables demand.
Consumables revenue grew to $14.0 million, instruments to $7.4 million, and services to $4.7 million, lifting gross margin to 56% from 49% as manufacturing efficiencies improved. Operating expenses also rose sharply as the company invested in R&D and sales infrastructure, resulting in a wider net loss of $21.3 million.
Alamar ended the quarter with $64.6 million in cash and cash equivalents, then completed an April 2026 IPO that raised net proceeds of $197.8 million, converted $56.5 million of convertible notes into equity, and simplified its capital structure through stock conversions and a reverse split.
Alamar Biosciences, Inc. reported first quarter 2026 results showing rapid growth but continuing losses. Total revenue reached $26.0 million, up 99% from $13.1 million a year earlier, driven by strong instrument, consumable, and services demand.
Instrument revenue rose to $7.4 million, consumables to $14.0 million, and services and other to $4.7 million. Gross margin improved to 56% from 49% on higher volumes and a mix shift toward consumables. Operating expenses increased to $26.8 million, leading to an operating loss of $12.3 million.
Net loss widened to $21.3 million, including an $8.6 million loss on remeasurement of convertible notes. Cash, cash equivalents and restricted cash totaled $69.5 million as of March 31, 2026. After quarter end, Alamar completed its initial public offering, raising $197.8 million of net proceeds to strengthen its balance sheet.
Illumina Innovation Fund entities and director Nicholas Naclerio report a significant ownership stake in Alamar Biosciences, Inc. common stock. They are deemed to beneficially own 6,363,612 shares, representing 9.6% of Alamar’s common stock outstanding after its initial public offering.
The position arises from multiple preferred stock investments since 2020, an aggregate $8,927,259.98 in convertible promissory notes, and an IPO purchase of 235,294 shares of common stock at $17.00 per share for $3,999,998.00. All shares were acquired using investment funds from Illumina Innovation Fund II and III investors.
The funds describe their holdings as for general investment purposes and may increase or decrease their position depending on market and company conditions. Illumina Innovation Fund II and III are subject to a 180‑day lock-up agreement after the IPO underwriting agreement, limiting near-term sales of their Alamar shares. Naclerio also serves on Alamar’s board and may receive additional equity compensation under the company’s 2026 equity incentive and director compensation plans.
Sands Capital Life Sciences Pulse Fund II, L.P. and affiliates report a 6.3% beneficial stake in Alamar Biosciences, Inc. following its initial public offering. They directly hold 4,230,926 shares of common stock, acquired through Series C preferred conversion, a convertible note conversion, and a 300,000-share IPO purchase at $17 per share.
The investors state they hold the shares for investment purposes and may buy or sell more depending on business and market conditions. Their holdings are subject to registration rights, a prior waiver for the IPO registration, and a 180-day lock-up that runs through October 13, 2026.
Alamar Biosciences, Inc. reported that investment vehicles affiliated with Qiming converted multiple series of preferred stock into equity tied to its initial public offering. Qiming-related funds converted Series A-3, Series A-4, Series B and Series C preferred stock into Class B Common Stock, and each Class B share was then automatically reclassified into Common Stock immediately before the IPO.
All transactions were indirect, recorded at a price of $0.00 per share, and coded as conversions or other internal restructurings rather than market purchases or sales. The Qiming general partner entities may be deemed to share voting and dispositive power but disclaim beneficial ownership beyond their proportionate economic interest.
Alamar Biosciences, Inc. reported insider activity by entities affiliated with the Illumina Innovation Funds around its initial public offering. On April 20, 2026, these reporting persons completed an open‑market purchase of 235,294 shares of Common Stock at $17.00 per share, held indirectly, bringing one reported Common Stock position to 507,076 shares following the transaction.
At the same time, multiple convertible promissory notes and series of Preferred Stock automatically converted into Class B Common Stock, and each share of Class B Common Stock was then reclassified into one share of Common Stock in connection with the IPO. These conversions and a related reclassification moved millions of shares from preferred and Class B instruments into Common Stock, leaving no remaining balance in the reported derivative securities.
The securities are held by Illumina Innovation Fund II, L.P. and Illumina Innovation Fund III, L.P., whose general partners and sole managing member, director Nicholas Naclerio, may be deemed to have voting and investment power but each disclaims beneficial ownership except to any pecuniary interest.